|Graham Miao |
President and CFO
Graham Miao is President and Chief Financial Officer of Pernix Therapeutics where he leads finance, operations, regulatory and scientific affairs. Mr. Miao served as a senior advisor to the CEO and Board of Directors of Pernix from May to July 2016. Prior to Pernix, Mr. Miao was Executive Vice President and CFO of PDI Inc., a NASDAQ-listed healthcare commercialization company from 2014 to 2016 where he helped achieve double-digit revenue growth, a turnaround of the business into profitability and the successful sale of PDI to Publicis Healthcare. From 2011 to 2014, Mr. Miao served as EVP and CFO and was appointed additional roles as Co-President and Co-Chief Executive Officer of Delcath Systems, Inc., a NASDAQ-listed specialty pharmaceutical and medical device company focused on cancer treatment. At Delcath, Mr. Miao raised over $100 million that funded the company’s transition to commercialization in Europe and expanded clinical development programs in the US. From 2009 to 2011, Mr. Miao served as Chief of Staff for the Global CFO Organization at Dun & Bradstreet, a NYSE-listed global commercial information service company. Previously, Mr. Miao was EVP & CFO of Pagoda Pharmaceuticals, a specialty pharmaceuticals and medical device company that was acquired by GlaxoSmithKline. Prior to that, Mr. Miao was Vice President of Strategic Planning & Financial Analysis at Symrise Inc., a global supplier of flavoring and fragrance products. Mr. Miao also worked at Schering-Plough Corporation, serving as division CFO for the company’s $3 billion primary care pharmaceuticals franchise. Prior to Schering-Plough, Mr. Miao held senior management positions at Pharmacia Corporation, including Finance Director and division CFO for the company’s $1.3 billion global oncology franchise where he led finance teams across marketing, sales, medical affairs and business development. While at Pharmacia, Mr. Miao helped structure and negotiate transactions in M&A, in-licensing, out-licensing and divestiture with an aggregate value of over $6 billion. Earlier in his career, Mr. Miao worked as a biotechnology equity analyst at JP Morgan & Co. and a scientist in cancer and neuroscience R&D at Roche.
Mr. Miao earned an M.B.A. in finance and management and a Ph.D. in biological sciences from Columbia University, an M.S. in molecular biology from Arizona State University, and a B.S. in biology from Fudan University in Shanghai, China.